Chinese biotechnology company CARsgen has finished enrolling subjects in its Phase II trial of satri-cel, a potential first-in-class CAR T-cell therapy for advanced gastric cancer, in China.
The trial is evaluating the efficacy and safety of satri-cel in treating patients with advanced gastric/gastroesophageal junction cancers (GC/GEJ) who have exhausted other treatment options.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Satri-cel is a Claudin18.2 CAR T-cell therapy that targets Claudin18.2, a protein frequently found in GC/GEJ and pancreatic cancer cells.
The open-label, multicentre, randomised study will compare the effects of satri-cel against those of standard therapies chosen by physicians, including paclitaxel, docetaxel, irinotecan, apatinib and nivolumab.
CARsgen Therapeutics founder, board chairman, CEO and chief scientific officer Dr Zonghai Li said: “We are very pleased to announce the successful completion of patient enrolment in the pivotal Phase II clinical trial of satri-cel in China.
“This significant milestone marks another solid step forward in our development of CAR T-cell therapies for solid tumours.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“We look forward to the submission of a new drug application and approval in China to benefit patients with gastric cancer.”
Satri-cel has previously demonstrated promising results in early-stage clinical evaluations.
In the Phase I CT041-CG4006 trial, the drug was reported to be well-tolerated, with no reports of dose-limiting toxicities, severe cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome.
The efficacy data from the same trial showed an overall response rate of 54.9% among 51 GC/GEJ patients treated with satri-cel, with a 96.1% disease control rate and a median response duration of 6.4 months.
Phase Ib results from the CT041-ST-01 trial showed overall response and disease control rates of 57.1% and 78.6% respectively among GC/GEJ patients who had previously undergone at least two lines of therapy.
Ongoing trials for Satri-cel include the investigator-initiated trials CT041-CG4006 and NCT03874897, as well as a confirmatory Phase II clinical trial for advanced GC/GEJ in China.
Cell & Gene therapy coverage on Clinical Trials Arena is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
